# Tirbanubulin (Klisiry®) in the Treatment of Basal Cell Carcinoma

> **NCT06112522** · PHASE2 · UNKNOWN · sponsor: **Centre Hospitalier Universitaire de Nice** · enrollment: 50 (estimated)

## Conditions studied

- Cell Carcinoma

## Interventions

- **DRUG:** Tirbanibulin

## Key facts

- **NCT ID:** NCT06112522
- **Lead sponsor:** Centre Hospitalier Universitaire de Nice
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-02-16
- **Primary completion:** 2024-12-01
- **Final completion:** 2025-12-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2024-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06112522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06112522, "Tirbanubulin (Klisiry®) in the Treatment of Basal Cell Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06112522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*